This article is part of Ophthalmology Advisor’s conference coverage from the 2021 meeting of the American Academy of Ophthalmology, held in New Orleans from November 12 to 15, 2021. The team at Ophthalmology Advisor will be reporting on a variety of the research presented by the ophthalmology experts at the AAO. Check back for more from the AAO 2021 Meeting.
Adverse events (AE) in patients who use teprotumumab to control inflammation and proptosis associated with thyroid eye disease are common, according to a presentation at the American Academy of Ophthalmology 2021 meeting, held in New Orleans, November 12-15. However, most of these AEs were mild to moderate, and were reversible, presenters reported.
The researchers reported on a case series of 51 patients undergoing treatment. The study took into account patients from 3 centers who were monitored for AEs and had a mean follow-up of 35 weeks. The researchers found that 40 patients (78%) did develop some form of AE related to the treatment. These AEs included muscle cramps (58%), diarrhea (40%), hair loss (33%), fatigue (23%), hearing loss (23%), hyperglycemia (18%), and rash (10%). The researchers reported that 80% of the AEs were mild to moderate and did not require treatment alteration or interruption. Intervention was required in 8 patients (20%), including 2 whose treatment was suspended temporarily and 6 who ceased using the therapeutic altogether.
Mean time to development of AEs was after 2 infusions (range: 1-5 infusions). In most patients (n=25, 63%) AEs either resolved or improved, and in 12 (30%) persistent symptoms were noted at last follow-up.
Since a small percentage of AEs did require interruption or cessation of therapy, the presenters noted that “protocols for screening, prevention and management of AEs are therefore advised.”
Sears CM, Kang JY, Clauss KD, Cockerham K, Wester ST, Kossler AN. Teprotumumab-related adverse events in TED. Paper presented at the American Academy of Ophthalmology 2021 Annual Meeting; November 12-15, 2021; New Orleans. Abstract PA058.